GSK3532795, formerly known as BMS-955176 (1), is a potent, orally active, second-
generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. The …

We previously reported a bi-functional betulinic acid derivative, A12-2 (4), containing an
optimized C-28 side chain that exhibits potent anti-HIV activity by inhibiting both HIV-1 entry …

The design and synthesis of a series of C28 amine-based betulinic acid derivatives as HIV-1
maturation inhibitors is described. This series represents a continuation of efforts following …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
48946098&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Compounds having drug and bio-affecting properties, their pharmaceutical compositions
and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that …

We have recently reported on the discovery of a C-3 benzoic acid (1) as a suitable
replacement for the dimethyl succinate side chain of bevirimat (2), an HIV-1 maturation …

In our continuing study of triterpene derivatives as potent anti-HIV agents, different C-3
conformationally restricted betulinic acid (BA, 1) derivatives were designed and synthesized …

Two betulinic acid derivatives, RPR103611 (2) and IC9564 (3) were previously reported to
be potent HIV-1 entry inhibitors. In this current study, a SAR study of the triterpenoid moiety …

An investigation of the structure–activity relationships of a series of HIV-1 maturation
inhibitors (MIs) based on GSK3640254 (4) was conducted by incorporating novel C-17 …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
53002809&utm_source= google_patent&utm_medium= platform_link&utm_campaign …